Platelet Rich Plasma in Plantar Fasciitis (PRP)

Minia University

Status: Completed

Conditions: Plantar Fascitis

Treatments: Drug: MethylPREDNISolone 40 MG; Other: platelet rich plasma

Study type: Interventional

Funder types: Other

Identifiers

NCT05339542

Rheumatology Dep.

Details and patient eligibility

About

a number of patient diagnosed as degenerative plantar fasciitis will be collected and divided into two groups, group I will be injected by platelet rich plasma and group II will be injected methylprednisolone

Full description

the study will include 100 patients diagnosed as degenerative plantar fasciitis and will be evaluated by musculoskeletal ultrasound by two observes and the will divided randomly into two groups who will be injected under ultrasound imaging by either Platelet rich plasma or methylprednisolone. selection of patient will be randomly and the study will be double blinded.

Enrollment: 98 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

* Clinical diagnosis of plantar fasciitis

Exclusion Criteria (history or current):

• Rheumatic diseases
• Foot Trauma
• Neurological diseases
• Thyroid disease
• Diabetes mellitus
• Chronic Renal Failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

98 participants in 2 patient groups

Platelet rich plasma group

Experimental group

Description:

platelet rich plasma (PRP) will be produced through whole blood centrifuge using a specific methodology in a strict aseptic setting. Then, blood will be collected and mixed with anticoagulant and Citrate-phosphate-dextrose adenine in a 10 volume blood to 1 volume anticoagulant ratio. The blood will be centrifuged for 10 minutes at 1000 rpm. Afterward, the plasma will be transferred to a new glass tube and centrifuged for 15 minutes at 3000 rpm. At the bottom of the tube, platelets will form a pellet. Finally, pure platelet-rich plasma will be obtained at a concentration of up to four times higher than baseline. Prior to the injection, calcium gluconate will be combined with PRP (at a ratio of 0.3 ml ca gluconate/ml PRP). The injection will be done once.

Treatment:

Other: platelet rich plasma

Methylprednisolone group

Active Comparator group

Description:

2 ml methylprednisolone acetate 40mg/ml (total 80mg methylprednisolone acetate) together with 1 ml lidocaine 2% (total 3 ml solution) will be directly injected under ultrasound guidance to the plantar fascia.This group serves as active comparative group. The injection will be done once.

Treatment:

Drug: MethylPREDNISolone 40 MG